KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vir Biotechnology (VIR) Cash & Equivalents (2018 - 2025)

Vir Biotechnology (VIR) has disclosed Cash & Equivalents for 8 consecutive years, with $232.2 million as the latest value for Q4 2025.

  • Quarterly Cash & Equivalents rose 159.76% to $232.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $232.2 million through Dec 2025, up 159.76% year-over-year, with the annual reading at $232.2 million for FY2025, 159.76% up from the prior year.
  • Cash & Equivalents hit $232.2 million in Q4 2025 for Vir Biotechnology, up from $170.1 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $963.7 million in Q3 2022 to a low of $8.6 million in Q1 2021.
  • Historically, Cash & Equivalents has averaged $204.1 million across 5 years, with a median of $88.8 million in 2024.
  • Biggest five-year swings in Cash & Equivalents: surged 4251.5% in 2021 and later plummeted 98.63% in 2023.
  • Year by year, Cash & Equivalents stood at $347.8 million in 2021, then crashed by 96.35% to $12.7 million in 2022, then soared by 1805.02% to $241.6 million in 2023, then plummeted by 63.0% to $89.4 million in 2024, then surged by 159.76% to $232.2 million in 2025.
  • Business Quant data shows Cash & Equivalents for VIR at $232.2 million in Q4 2025, $170.1 million in Q3 2025, and $211.1 million in Q2 2025.